Edwards Lifesciences Corporation’s Stock Price Soars to $93.81, Registering a Robust 6.20% Increase

Edwards Lifesciences Corporation (EW)

93.81 USD +5.48 (+6.20%) Volume: 6.84M

Edwards Lifesciences Corporation’s stock price soars to 93.81 USD, marking a significant increase of +6.20% in today’s trading session with a high trading volume of 6.84M, further strengthening its robust YTD performance of +22.02%.

Latest developments on Edwards Lifesciences Corporation

Edwards Lifesciences (EW) stock has seen a 2% increase since its last earnings report, with key factors being the global adoption of RESILIA and TAVR growth. The company’s stock has outperformed competitors on strong trading days, despite occasional losses, earning shareholders a 8.3% CAGR over the last five years. Analyst upgrades and price target boosts have further instilled confidence in the stock’s potential. Major investments from Crestwood Advisors Group and Kiwi Wealth Investments, despite some reductions by AQR Capital Management and Sands Capital Management, have also positively influenced the stock’s performance.

A look at Edwards Lifesciences Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Edwards Lifesciences, a company that specializes in treating cardiovascular disease, has a bright long-term outlook according to the Smartkarma Smart Scores. With a score of 4 for growth and momentum, the company is expected to see strong growth and continue to perform well in the market. This is supported by their diverse product offerings, which include tissue replacement heart valves, monitoring devices, and pharmaceuticals, that are in high demand globally.

While the company scores on the lower end for value and dividend at 2 and 1 respectively, their resilience score of 3 indicates a stable financial standing. This is important for a company in the healthcare industry, where stability is key in weathering any potential market fluctuations. Overall, the Smart Scores suggest that Edwards Lifesciences is positioned for long-term success and investors can expect to see continued growth and momentum from the company in the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma